<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction Schema extraction-schema-148 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extraction Schema Details for extraction-schema-148</h1>

        <div class="section">
            <h2>Extraction Schema (General Information)</h2>
            <div class="info-section">
                <p><strong>Schema ID:</strong> extraction-schema-148</p>
                <p><strong>Extraction Query:</strong> Extract any mentions of neuronal populations within the visual (occipital) cortex that show selective vulnerability or resistance to amyloid‑β plaques or tau tangles in dementia, including details on cell type, cortical layer, subregion, pathology type, reported mechanisms, experimental models, quantitative measures, species, disease stage, and any contrasting findings.</p>
            </div>
        </div>

        <div class="section">
            <h2>Extraction Schema (Details)</h2>
            <table>
                <thead>
                    <tr>
                        <th style="width: 20%;">Field Name</th>
                        <th style="width: 15%;">Type</th>
                        <th style="width: 65%;">Description</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>neuronal_population</strong></td>
                        <td>str</td>
                        <td>Specific neuronal population described (e.g., 'layer 5 pyramidal neurons', 'parvalbumin-positive interneurons', 'intratelencephalic excitatory cells').</td>
                    </tr>
                    <tr>
                        <td><strong>cortical_subregion</strong></td>
                        <td>str</td>
                        <td>Visual‑cortex subregion or area (e.g., 'primary visual cortex (V1)', 'V2', 'V4', 'extrastriate cortex').</td>
                    </tr>
                    <tr>
                        <td><strong>cortical_layer</strong></td>
                        <td>str</td>
                        <td>Cortical layer(s) where the population resides (e.g., 'L2/3', 'L5', 'L6').</td>
                    </tr>
                    <tr>
                        <td><strong>vulnerability_status</strong></td>
                        <td>str</td>
                        <td>Whether the population is reported as 'vulnerable', 'resistant', 'mixed', or 'unknown' to the pathology.</td>
                    </tr>
                    <tr>
                        <td><strong>pathology_type</strong></td>
                        <td>str</td>
                        <td>Type of AD pathology associated with the finding (e.g., 'amyloid‑β plaques', 'tau tangles', 'both').</td>
                    </tr>
                    <tr>
                        <td><strong>evidence_source</strong></td>
                        <td>str</td>
                        <td>Source of the evidence (e.g., 'human postmortem', 'APP/PS1 transgenic mouse', 'tau P301S rat model', 'in vitro neuronal culture').</td>
                    </tr>
                    <tr>
                        <td><strong>experimental_method</strong></td>
                        <td>str</td>
                        <td>Method used to assess vulnerability (e.g., 'immunohistochemistry', 'confocal microscopy', 'RNA‑seq', 'single‑cell transcriptomics', 'PET imaging', 'electron microscopy').</td>
                    </tr>
                    <tr>
                        <td><strong>quantitative_measure</strong></td>
                        <td>str</td>
                        <td>Any quantitative data reported (e.g., 'plaque density 120 plaques/mm²', 'tau burden Braak stage III', '20% loss of PV+ cells', 'fold‑change in APP expression').</td>
                    </tr>
                    <tr>
                        <td><strong>reported_mechanism</strong></td>
                        <td>str</td>
                        <td>Proposed biological mechanism(s) explaining vulnerability or resistance (e.g., 'high NMDA‑receptor expression', 'elevated oxidative stress', 'low mitochondrial density', 'enhanced autophagy', 'synaptic hyperactivity').</td>
                    </tr>
                    <tr>
                        <td><strong>associated_genes_proteins</strong></td>
                        <td>str</td>
                        <td>Genes, proteins, or molecular markers linked to the finding (e.g., 'APOE ε4', 'BACE1', 'tau phosphorylated at Ser202', 'GAD67', 'CaMKII').</td>
                    </tr>
                    <tr>
                        <td><strong>species</strong></td>
                        <td>str</td>
                        <td>Species studied (e.g., 'Homo sapiens', 'Mus musculus', 'Rattus norvegicus').</td>
                    </tr>
                    <tr>
                        <td><strong>disease_stage</strong></td>
                        <td>str</td>
                        <td>Stage of dementia/AD referenced (e.g., 'early AD', 'Mild Cognitive Impairment', 'Braak stage III–IV').</td>
                    </tr>
                    <tr>
                        <td><strong>counter_evidence</strong></td>
                        <td>str</td>
                        <td>Any reported contradictory or null findings regarding the same neuronal population or region.</td>
                    </tr>
                    <tr>
                        <td><strong>reference_citation</strong></td>
                        <td>str</td>
                        <td>Short citation or DOI to identify the source paper.</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <div class="section">
            <h2>Extraction Schema (Debug)</h2>
            <pre><code>{
    "id": "extraction-schema-148",
    "schema": [
        {
            "name": "neuronal_population",
            "type": "str",
            "description": "Specific neuronal population described (e.g., 'layer 5 pyramidal neurons', 'parvalbumin-positive interneurons', 'intratelencephalic excitatory cells')."
        },
        {
            "name": "cortical_subregion",
            "type": "str",
            "description": "Visual‑cortex subregion or area (e.g., 'primary visual cortex (V1)', 'V2', 'V4', 'extrastriate cortex')."
        },
        {
            "name": "cortical_layer",
            "type": "str",
            "description": "Cortical layer(s) where the population resides (e.g., 'L2/3', 'L5', 'L6')."
        },
        {
            "name": "vulnerability_status",
            "type": "str",
            "description": "Whether the population is reported as 'vulnerable', 'resistant', 'mixed', or 'unknown' to the pathology."
        },
        {
            "name": "pathology_type",
            "type": "str",
            "description": "Type of AD pathology associated with the finding (e.g., 'amyloid‑β plaques', 'tau tangles', 'both')."
        },
        {
            "name": "evidence_source",
            "type": "str",
            "description": "Source of the evidence (e.g., 'human postmortem', 'APP/PS1 transgenic mouse', 'tau P301S rat model', 'in vitro neuronal culture')."
        },
        {
            "name": "experimental_method",
            "type": "str",
            "description": "Method used to assess vulnerability (e.g., 'immunohistochemistry', 'confocal microscopy', 'RNA‑seq', 'single‑cell transcriptomics', 'PET imaging', 'electron microscopy')."
        },
        {
            "name": "quantitative_measure",
            "type": "str",
            "description": "Any quantitative data reported (e.g., 'plaque density 120 plaques/mm²', 'tau burden Braak stage III', '20% loss of PV+ cells', 'fold‑change in APP expression')."
        },
        {
            "name": "reported_mechanism",
            "type": "str",
            "description": "Proposed biological mechanism(s) explaining vulnerability or resistance (e.g., 'high NMDA‑receptor expression', 'elevated oxidative stress', 'low mitochondrial density', 'enhanced autophagy', 'synaptic hyperactivity')."
        },
        {
            "name": "associated_genes_proteins",
            "type": "str",
            "description": "Genes, proteins, or molecular markers linked to the finding (e.g., 'APOE ε4', 'BACE1', 'tau phosphorylated at Ser202', 'GAD67', 'CaMKII')."
        },
        {
            "name": "species",
            "type": "str",
            "description": "Species studied (e.g., 'Homo sapiens', 'Mus musculus', 'Rattus norvegicus')."
        },
        {
            "name": "disease_stage",
            "type": "str",
            "description": "Stage of dementia/AD referenced (e.g., 'early AD', 'Mild Cognitive Impairment', 'Braak stage III–IV')."
        },
        {
            "name": "counter_evidence",
            "type": "str",
            "description": "Any reported contradictory or null findings regarding the same neuronal population or region."
        },
        {
            "name": "reference_citation",
            "type": "str",
            "description": "Short citation or DOI to identify the source paper."
        }
    ],
    "extraction_query": "Extract any mentions of neuronal populations within the visual (occipital) cortex that show selective vulnerability or resistance to amyloid‑β plaques or tau tangles in dementia, including details on cell type, cortical layer, subregion, pathology type, reported mechanisms, experimental models, quantitative measures, species, disease stage, and any contrasting findings.",
    "supporting_theory_ids": [],
    "model_str": "openrouter/openai/gpt-oss-120b"
}</code></pre>
        </div>
    </div>
</body>
</html>